Chronic obstructive pulmonary disease
- 15 May 2003
- Vol. 326 (7398), 1046-1047
- https://doi.org/10.1136/bmj.326.7398.1046
Abstract
Footnotes Competing interests DP, either through his role at the University of Aberdeen or personally, has received grants, honorariums, or educational support from the UK NHS research and development programme and the following pharmaceutical companies: 3M, Abbott, AstraZeneca, GlaxoSmithKline, Innovata Biomed, Ivax, Merck, Sharpe and Dohme, Medeva, Novartis, Roche, Schering Plough, Yamanouchi. He does not possess any pharmaceutical shares. In the past two years MD has received payment from 3M and Altana Pharma for consultancy and a research grant from Ivax. These companies produce respiratory products.Keywords
This publication has 7 references indexed in Scilit:
- Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal surveyJournal of Public Health, 2002
- Smoking and Lung Function of Lung Health Study Participants after 11 YearsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary.2001
- Randomised controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary diseaseThorax, 2000
- The Prevalence of COPDChest, 2000
- Socioeconomic status and chronic obstructive pulmonary diseaseThorax, 1999
- BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS.1997